AI-generated summary reviewed by our newsroom. Read our AI Policy. Durham paused its code hearing citing the 2024 law and lawsuit threats. State law requires written owner consent to cut density, uses ...

Olsen provided 2026 guidance with “same-store NOI growth in a range between 0.3% and 2%,” core revenue growth between 1.3% and 2.5%, and core expense growth between 3% and 4%. The company projects ...

AMESBURY — A preapplication for a proposed 68-unit residential development stretched over four parcels of land went before the Planning Board earlier this week. Applicants for the development, 230 ...

The owners of Colony Ridge, a Houston-area developer accused of running a predatory lending scheme that deceived Latinos, agreed to a sweeping legal settlement that will require them to invest in law ...

Never miss a story with The Brief, our free newsletter. Keep tabs on Texas politics and policy with our morning newsletter. The Texas Tribune Independent news. Trusted by Texans. About The Texas ...

Polkadot is down 68% over the past year despite strong developer activity and major network upgrades. The cryptocurrency's ETF filings from Grayscale and 21Shares are still awaiting SEC approval. The ...

The Copilot Studio extension lets developers use any VS Code-compatible AI assistant to develop AI agents, then sync with Copilot Studio for testing and iteration. Microsoft is offering a Microsoft ...

Harry Styles seemingly signaled the dawn of a new musical era when he posted an 8-minute-long video to his YouTube channel on Dec. 27, 2025. A new website, webelongtogether.co, has mysteriously popped ...

Harry Styles has launched a new website amid speculation he's gearing up for a comeback. Speculation around the As It Was hitmaker's next move has been heating up, with industry insiders suggesting ...

LOS ANGELES — Fans of Harry Styles are buzzing with excitement after a series of mysterious posters and a new website popped up this week, leading many to believe the pop star may be ready to return ...

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M. In a ...